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Abstract
Background: To elucidate mechanisms involved in multiple sclerosis (MS), we studied genetic regulation of experimental
autoimmune encephalomyelitis (EAE) in rats, assuming a conservation of pathogenic pathways. In this study, we focused on
Eae23, originally identified to regulate EAE in a (LEW.1AV1xPVG.1AV1)F2 cross. Our aim was to determine whether one or
more genes within the 67 Mb region regulate EAE and to define candidate risk genes.
Methodology/Principal Findings: We used high resolution quantitative trait loci (QTL) analysis in the 10th generation (G10)
of an advanced intercross line (AIL) to resolve Eae23 into two QTLs that independently regulate EAE, namely Eae23a and
Eae23b. We established a congenic strain to validate the effect of this region on disease. PVG alleles in Eae23 resulted in
significant protection from EAE and attenuated CNS inflammation/demyelination. Disease amelioration was accompanied
with increased levels of Foxp3
+ cells in the CNS of the congenic strain compared to DA. We then focused on candidate gene
investigation in Eae23b, a 9 Mb region linked to all clinical phenotypes. Affymetrix exon arrays were used to study
expression of the genes in Eae23b in the parental strains, where none showed differential expression. However, we found
lower expression of exon 4 of ZEB1, which is specific for splice-variant Zfhep1. ZEB1 is an interleukin 2 (IL2) repressor involved
in T cell development. The splice-specific variance prompted us to next analyze the expression of ZEB1 and its two splice
variants, Zfhep1 and Zfhep2, in both lymph node and spleen. We demonstrated that ZEB1 splice-variants are differentially
expressed; severity of EAE and higher IL2 levels were associated with down-regulation of Zfhep1 and up-regulation of
Zfhep2.
Conclusions/Significance: We speculate that the balance between splice-variants of ZEB1 could influence the regulation of
EAE. Further functional studies of ZEB1 and the splice-variants may unravel novel pathways contributing to MS
pathogenesis and inflammation in general.
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory disease of the
central nervous system (CNS), classified as a complex immunopath-
ological disease that depends on interactions between genetic and
environmental factors [1,2]. Observations in twin cohorts and
familial aggregation studies have demonstrated the genetic compo-
nent of MS etiology [3–5] and an influence from genes within the
major histocompatibility complex (MHC, HLA in humans) is
well established [6–10]. Recently, a few non-HLA genes have un-
ambiguously been associated with MS susceptibility, including
IL2RA (ENSG00000134460), IL7R (ENSG00000168685), CD58
(ENSG00000116815) and CLEC16A (ENSG00000038532) [11–15].
The ongoing challenge is to elucidate the molecular mechanisms
conferred by the risk genes. Therefore, analyses in a simplified
system are advocated.
The genetic dissection of a rat model for MS represents such an
approach, with the assumption that there are conserved
mechanisms regulating neuroinflammation among species. We
study the genetic regulation of myelin oligodendrocyte glycopro-
tein (MOG) induced experimental autoimmune encephalomyelitis
(EAE) in rats due to a close mimicry with MS, with a protracted
relapsing disease course, inflammatory infiltrates, prominent
demyelination and axonal damage [16]. Consistent with MS, the
MHC locus is suggested to be the strongest susceptibility locus in
EAE [17]. Furthermore, non-MHC loci that contribute to EAE
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12716susceptibility have been identified in several F2 crosses using
different strain combinations [18–20]. However, the determina-
tion of disease-regulating genes requires further fine-mapping and
validation approaches.
Here we use an approach combining high-resolution mapping
in an advanced intercross line (AIL) with congenic validation and
gene expression studies. This approach has successfully been used
to identify EAE-regulating genes. An influence of Eae18 on MOG-
EAE was confirmed in a congenic strain [21] and the region was
fine-mapped in the AIL to identify a cluster of chemokine genes as
candidate genes [22]. Further investigation demonstrated associ-
ation of CCL1 (ENSG00000108702), CCL2 (ENSG00000108691)
and CCL12 (ENSRNOG00000029768) with MS [23]. Here we
focused on another region, on rat chromosome 17 (RNO17) that
was originally identified in a (LEW.1AV1xPVG.1AV1)F2 cross,
where linkage analysis revealed a quantitative trait locus (QTL)
regulating clinical and histopathological signs of EAE (named
Eae23 in this study) [20].
Our aim was to determine whether one or more genes within
the 67 Mb region of Eae23 regulate EAE and to fine-map those
genes. Eae23 was resolved into two QTLs that independently
regulate EAE, namely Eae23a and Eae23b. The effect of Eae23 was
confirmed in a congenic strain, DA.PVG-Eae23, and histopatho-
logical investigation of the CNS showed that inflammation and
demyelination was attenuated compared to DA. We identified
ZEB1 (Zfhep, TCF8, dEF1, ZFHX1A, ENSRNOG00000017863) as
the most likely candidate gene in Eae23b. ZEB1 is foremost known
as a repressor of interleukin 2 (IL2, ENSRNOG00000017348), a
cytokine involved in proliferation, apoptosis, cell differentiation
and T cell development at multiple stages [24,25]. We further
postulate that the balance between splice variants of ZEB1 could
influence the regulation of EAE.
Results
Determination of Eae23a and Eae23b using an Advanced
Intercross Line
To narrow the confidence interval of Eae23 [20], and confirm
the locus in a new strain combination, we investigated the region
in the (DAxPVG.1AV1)G10 AIL [26–29]. In total, 224 out of 772
AIL animals displayed clinical EAE, with an incidence of 29%
(Figure S1). G10 AIL rats were genotyped over 67.7 Mb of
RNO17 (13.9–81.6 Mb) using 20 polymorphic microsatellite
markers (Table S1). Linkage analysis was performed in females
due to a lack of power to detect the QTL in males (Figure S2).
Analysis of clinical phenotypes identified two QTLs, denominated
Eae23a and Eae23b (Figure 1).
Eae23a was linked to all clinical phenotypes and constituted a
21 Mb region around peak marker D17Got45 at 47.3 Mb
(Table 1). The confidence interval was likely overestimated owing
in part to all 11 microsatellite markers tested between D17Rat12
(33.3 Mb) and D17Got49 (42.7 Mb) being non-polymorphic in
the strains used. The allelic effect showed transgressive segregation
with alleles from the resistant PVG strain promoting disease in a
dominant manner (Figure 1B). Rats homozygous for DA alleles
were protected against EAE with lower incidence (p,0.0002),
later onset (p,0.0005), shorter duration of disease (p,0.0004) and
with lower maximum and cumulative EAE scores (p,0.0008 and
p,0.0006, respectively) when compared to rats with heterozygote
or PVG homozygote genotype in Eae23a.
Eae23bwasalsolinkedto allclinical phenotypes,witha confidence
interval of 9 Mb (57–66 Mb) around peak markers D17Got120 and
D17Got70 at 61.8–62.3 Mb (Table 1). Analysis of allelic effects
revealed significant heterosis whereby heterozygous alleles differ
from either parental allele (Figure 1C). Rats heterozygous in Eae23b
were predisposed to EAE with higher incidence (p,0.0001), earlier
onset (p,0.0001), longer duration (p,0.0001) and more severe
disease (MAX p,0.0001, CUM p,0.0001) when compared to rats
with homozygous DAorPVGgenotypeinEae23b.A striking 43%of
Eae23b-heterozygous rats were affected by EAE, compared to only
27% of the homozygous rats.
The individual effects of Eae23a and Eae23b on EAE phenotype
variation were further supported by a fit multiple QTL model [30]
(Table 1). To estimate the probability of these QTLs contributing
to EAE, simulated pedigrees were mapped using a single-QTL
model (to force the QTLs to compete for effect). Consistent with
the linkage analysis, Eae23a and Eae23b were both probable to
influence susceptibility and severity phenotypes (Table 1).
Confirmation of Eae23 Effects on EAE using Congenic
Rats
To confirm the influence of Eae23 on disease we established
DA.PVG-Eae23, a congenic strain that carries PVG alleles in
Eae23a and Eae23b introgressed on a DA background (Figure 2).
Commonly, the parental DA strain displays a relapsing-remitting
disease course with an average onset of EAE around two weeks
after immunization, while the parental PVG.1AV1 strain is
resistant to the same induction protocol. DA.PVG-Eae23 litter-
mate controls showed no clinical differences to inbred DA (data
not shown) and DA were therefore used as control in the
experiments. To follow up the AIL findings we first investigated
the clinical effects in females during MOG-EAE. In total, 20 of the
25 female rats included in the experiment showed signs of EAE
(80% incidence). Although there was no significant difference in
susceptibility (INC and ONS) between strains, DA.PVG-Eae23
rats had significantly less severe clinical symptoms compared to
DA during both the acute and chronic phase of disease (Figure 3A).
DA.PVG-Eae23 female rats had less severe disease, with lower
maximum (p,0.02) and cumulative (p,0.007) EAE scores and
shorter duration of disease (p,0.01) (Table 2). In total, 34 of 43
male rats included in the experiment developed EAE (79%
incidence) which was comparable with the incidence in females.
DA.PVG-Eae23 males had less severe disease during the acute and
chronic phases compared to DA, and had a lower maximum EAE
score (p,0.04) (Figure 3B, Table 2).
To investigate if the heterosis effect of Eae23b detected in the
AIL could be captured in the congenic strain, we repeated the
experiment with heterozygous DA.PVG-Eae23 rats. Based on the
AIL results we expected heterozygous DA.PVG-Eae23 rats to have
the full effect of both Eae23a and Eae23b (PVG dominance and
heterosis, respectively) with a more severe disease, while
homozygous rats should show effect of Eae23a only (PVG
dominance) and have an intermediate phenotype. However, there
were no significant differences between heterozygous DA.PVG-
Eae23 and DA (Figure 3C). Although the homozygous DA.PVG-
Eae23 rats were significantly protected compared to DA (consistent
with the previous experiments), more rats in total were affected by
EAE (93% incidence) and the congenic rats showed slightly
increased disease severity. Since both female experiments were
immunized with the same protocol, this slight variation may reflect
inter-experiment fluctuation or a seasonal influence (winter
compared to spring) on EAE [31]. To understand the lack of
effect in heterozygous congenic rats, we selected individuals from
the AIL cohort that matched the genotype combinations captured
in the congenic rats (Table 3). This analysis was consistent with the
results from congenic rats, since the allele combination captured in
the heterozygous congenic rats also produced an intermediate
phenotype in the AIL that was not significantly different from the
Eae23 in Neuroinflammation
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further investigate the heterosis effect in the congenic strain.
Influence of Eae23 on CNS pathology in Congenic Rats
To evaluate the effects of Eae23 on EAE pathology in the target
organ, we investigated inflammation and demyelination in the
CNS of DA and DA.PVG-Eae23 female rats at 35 days post
immunization (p.i.). Immunohistopathological analysis of the brain
and the spinal cord revealed differences in inflammation/
demyelination, as well as in cell activation and infiltration between
strains (Figure 4). The most frequent distribution pattern (41%
overall) was characterized by the combined appearance of
demyelinated lesions in the optic nerves and the spinal cord.
The control group (DA) developed more severe disease compared
to the congenic strain (Table 4). However, when we compared rats
with the same MAX and ONS, congenic rats showed generally
lower susceptibility for CNS inflammation with a lower degree of
demyelination and with a lower number of eosinophils and
infiltrating CD8
+ macrophages [32]. We also observed a lower
recruitment of the CD3
+ T cell population to the spinal cord in
congenic rats (indicated by arrow heads in Figure 4). The
distribution pattern of CD3
+ T cells, CD8
+ macrophages and
Figure 1. Two QTLs regulate EAE: Eae23a and Eae23b. A) A log-likelihood plot of Eae23 regulating selected EAE phenotypes in
(DAxPVG.1AV1)G10 AIL females (N=428). Peak markers are D17Got45 for Eae23a and D17Got120 (ONS and DUR) and D17Got70 (INC, MAX and CUM)
for Eae23b, and both QTLs displayed linkage to all clinical phenotypes. Microsatellite marker positions are indicated by vertical lines on the x-axis,
retrieved from Ensembl Genome Database (http://www.ensembl.orgv.55). B–C) Allelic effect plots for Eae23a and Eae23b in females (N=428) show
rats stratified according to their genotype at D17Got45 and D17Got70. MAX is representative for all clinical phenotypes. Phenotype codes: ONS =
grey, MAX = black, DUR = black dashed, WL = grey dashed.
doi:10.1371/journal.pone.0012716.g001
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and in the spinal cord. There was significantly less demyelination
in both brain and spinal cord of DA.PVG-Eae23 rats compared to
DA (p,0.01 and p,0.03, respectively). Interestingly, Foxp3
+ T
cells were present in higher numbers in the congenic rats
compared to DA (indicated by arrow heads in Figure 4).
Influence of Eae23 on regulatory T cell response to MOG
recall
To investigate the possibility of an enhanced population of
Foxp3
+ regulatory T cells (Tregs) in DA.PVG-Eae23,w e
determined the proportion of Foxp3-expressing T cells in lymph
nodes collected 7 days p.i. (Figure 5). Using flow cytometry, a
higher proportion of CD4
+CD25
+Foxp3
+ cells was detected in ex
vivo lymph node cells from the susceptible DA strain compared to
DA.PVG-Eae23 (N=5 per group; p=0.008; data not shown).
However, in response to MOG restimulation, DA.PVG-Eae23 had
a significantly higher up-regulation of the CD4
+CD25
+Foxp3
+
population than DA (2.6- and 1.8-fold change, respectively;
p=0.008; Figure 5C).
Expression Studies Identify ZEB1 as a Candidate EAE-
regulating gene
Eae23a contained 140 genes while Eae23b presented a limited
number of candidate genes to investigate further. On the
assumption that a shared gene is responsible for linkage between
Eae23b and all clinical phenotypes, we restricted the candidate gene
list to the region shared among clinical phenotypes. The 5 Mb
region (59–64 Mb) contained 30 genes, of which 21 had described
functions (Figure 2). mRNA expression of all candidate genes was
investigated in lymph nodes collected day 7 p.i. from parental DA
and PVG.1AV1 rats (N=4 per group) using exon arrays [33].
There were no differences in gene-level expression of the candidate
genes between strains that reached genome-wide significance.
When we investigatedexon-level expression of the genes, there were
no differences between parental strains. However, exon 4 of ZEB1
hadmuchlowerexpressioncomparedtoallotherexonsofthisgene,
indicating alternative splicing (Figure 6A). Interestingly, ZEB1
produces two splice variants, Zfhep1 (NP_037296.1, EN-
SRNOT00000046013) and Zfhep2 (ZEB1, ENSRNOT000000
24336), for which exon 4 (NP_037296.1 exon 1) is specific for the
Zfhep1 variant (Figure 6B). The resulting protein differs in the first
zinc finger cluster (Figure 6C). This prompted us to investigate if
splice-variant specific differences of ZEB1 could be involved in
regulation of EAE.
To explore potential differences in ZEB1 using the more
sensitive quantitative real-time polymerase chain reaction (RT-
PCR) method, we analyzed the mRNA expression of ZEB1 and its
target IL2 in lymph nodes collected at day 7 p.i. from MOG-
immunized DA and PVG.1AV1 rats (N=6 per group). There
were no significant differences between the strains in either the
shared region of ZEB1 or its downstream target IL2 (Figure 7).
However, mRNA expression of the splice variant Zfhep2 was
higher in DA compared to PVG.1AV1 (p,0.005) while there was
no significant difference in Zfhep1.
To investigate if Eae23 regulates this expression we then
measured ZEB1, splice variants and IL2 mRNA expression in
lymph nodes collected at day 7 p.i. from MOG-immunized DA
and DA.PVG-Eae23 female rats (N=10 and N=11, respectively)
(Figure 8A–D).
No significant differences between the strains were seen in ZEB1,
Zfhep1 or IL2. However, mRNA expression of the splice variant
Zfhep2 was higher in DA.PVG-Eae23 (p,0.018) compared to DA
(Figure 8D), confirming regulation by the Eae23 locus. Similarly, we
observed a trend of lower secreted IL-2 in DA.PVG-Eae23 upon
recall, although differences were not significant (Figure S3).
To further investigate the expressional differences in another tissue
at a later timepoint, we collected spleens from DA and DA.PVG-
Eae23 female rats on day 35 p.i (N=9 and N=13) (Figure 8E–H).
The shared region of ZEB1, Zfhep2 and IL2 were significantly up-
regulated in DA compared to DA.PVG-Eae23 (p,0.001, p,0.002
and p,0.002, respectively), while Zfhep1 was significantly down-
regulated in DA compared to DA.PVG-Eae23 (p,0.04).
Our data suggests that the balance in expression between Zfhep1
and Zfhep2 could contribute to disease protection in the congenic
strain, both in early initiation and ongoing disease.
Discussion
In this study, we used the AIL to resolve Eae23 into two narrow
QTLs that independently regulate EAE, namely Eae23a and Eae23b.
Table 1. Linkage of Eae23.
Phenotype
Eae23a LOD
Score
Peak Marker
Eae23a
a
LOD
S.I. =1.5
b
Eae23
Prob
c
Eae23b LOD
Score
Peak Marker
Eae23b
a
LOD
S.I. =1.5
b
Eae23
Prob
c
INC (1.9) 3.7 D17Got45* 36–57 22.4% 4.9 D17Got70** 59–66 69.2%
ONS (2.2) 4.4 D17Got45* 36–56 27.1% 5.6 D17Got120** 59–66 66.5%
MAX (2.4) 4.8 D17Got45** 36–56 37.1% 5.2 D17Got70** 57–64 55.5%
DUR (2.0) 4.8 D17Got45** 39–51 27.7% 5.1 D17Got120** 57–64 58.7%
CUM (1.7) 4.3 D17Got45* 43–54 31% 4.2 D17Got70* 57–64 51%
Linkage of Eae23 in 428 (DA6PVG.1AV1)G10 AIL female rats. The significance thresholds are indicated in parenthesis and are the maximum LOD scores obtained from
the analysis of residual values from family mean data for each phenotype.
aPeak marker indicates the microsatellite marker closest to the highest LOD score obtained within the QTL. The fit multiple QTL model was used to validate the
independent effects of Eae23a and Eae23b (phenotype = Eae23a + Eae23b + e) and the locations used corresponds to the peak markers. A significant difference in the
phenotypic variance defines an independent QTL, and is indicated by
*=p,0.05 and
**=p,0.01.
bA drop in LOD score of 1.5 from the maximum LOD (LOD support interval) was used to define the confidence intervals. Positions are given in Mb.
cProbabilities were calculated from simulated pedigrees as the percentage of times the maximum LOD was located within the confidence interval of each QTL.
Abbreviations: INC = incidence of EAE, ONS = onset of EAE, MAX = maximum EAE score, DUR = duration of EAE, CUM = cumulative EAE score, S.I = Support
Interval.
doi:10.1371/journal.pone.0012716.t001
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with a congenic strain. These approaches complemented each other
to provide evidence for Eae23‘s importance for neuroinflammation.
The congenic strain carrying PVG alleles in Eae23 demonstrat-
ed protection from clinical symptoms of disease and attenuated
CNS inflammation and demyelination. This was somewhat
surprising, as DA alleles in Eae23 were disease protective in the
AIL. Further, the combination of Eae23a DA/PVG alleles together
with Eae23b DA/PVG alleles (disease-driving in the AIL)
produced an intermediate phenotype, suggesting that the regula-
tory effects exerted by Eae23a and Eae23b may be influenced by
other regions in the genome. EAE is a multifactorial disease and
several regulatory regions and epistatic interactions that influence
EAE have previously been demonstrated in the AIL [27,28]. The
Figure 2. Summary of the Eae23 region on RNO17. A) Summary log-likelihood plot of Eae23. The black dashed line depicts the significance
threshold determined by the analysis of residual family values and the grey dashed line depicts a threshold of 3.4 [30]. Horizontal bars above the x-
axis indicate the confidence intervals of each QTL according to a 1.5 LOD support interval (clinical phenotypes are represented by MAX). Microsatellite
marker positions are indicated by vertical lines on the x-axis, retrieved from Ensembl Genome Database (http://www.ensembl.orgv.55). B) The open
box below the x-axis represents the region where PVG alleles were introgressed into a DA background in the DA.PVG-Eae23 congenic strain tested in
MOG-EAE. The black box indicates the confidence interval of Eae23b. C) The candidate genes investigated in this study: 30 genes contained within
Eae23b.
doi:10.1371/journal.pone.0012716.g002
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Eae23 to interact with and be influenced by other loci. Conversely,
these effects were fixed in the congenic strain in order to study
Eae23 in isolation. The AIL is therefore likely to capture more
accurate genetic effects in the complex setting and thus enable
QTL refinement, while the congenic strain represents the isolated
effect of alleles at a single locus and thus provides a good tool for
dissecting the molecular mechanisms involved in disease.
Figure 3. A congenic strain confirms the influence of Eae23 on EAE in females and males. Daily EAE scores in parental DA and congenic
DA.PVG-Eae23 demonstrate that congenic strains with PVG alleles in Eae23 are protected from EAE. A) Females; DA N=12 and DA.PVG-Eae23 N=13.
B) Males; DA N=22 and DA.PVG-Eae23 N=21. C) Females; DA N=16, DA.PVG-Eae23 N=13 and heterozygous DA.PVG-Eae23 N=13. Females are
represented by circles and males are represented by squares. Mann-Whitney U-test was used to compare the daily EAE scores; p values #0.05 were
considered significant and is indicated by *. Abbreviations: D.P-Eae23= DA.PVG-Eae23, Eae23-H = heterozygous DA.PVG-Eae23, p.i. = post
immunization. Vertical bars represent standard error of the mean (SEM).
doi:10.1371/journal.pone.0012716.g003
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member A1 (Btn1a1) is of particular interest because of its effects
in EAE. The extracellular Ig-like domain of butyrophilin shares
features with MOG that are suggested to allow molecular
mimicry, and butyrophilin can induce or suppress the encepha-
litogenic T cell response to MOG in DA rats [34]. Additionally,
butyrophilin can both prevent and suppress MOG-EAE in mice,
with subsequent suppression of IFN-c, IL-2 and IL-12 [35]. The
involvement of butyrophilin and other possible candidate genes
within Eae23a and their effect on EAE requires further
investigation that will be pursued in future studies.
For Eae23b, we defined ZEB1 as a possible candidate gene by
using isoform-specific expression profiling of the parental DA and
PVG.1AV1 and congenic strains. ZEB1 is a zinc finger
homeodomain transcription factor that binds E-box-like sequences
at target genes [36] and represses gene transcription by recruiting
the C-terminal-binding protein (CtBP) co-repressor [37–39]. ZEB1
is foremost known as an interleukin 2 (IL2) repressor [40,41].
Zfhep1, the full-length and fully functional splice-variant of ZEB1,
can down-regulate expression of its’ own gene in addition to other
genes. Conversely, splice-variant Zfhep2 antagonizes this auto-
repression by competing for the binding sites without repressing
ZEB1 expression [42]. Thus, increased expression of Zfhep2
disturbs auto regulation of Zfhep1 leading to subsequent up-
regulation of Zfhep1 that down-regulates IL2. In line with this, we
detected higher expression of Zfhep2 in the lymph node cells of
protected DA.PVG-Eae23 congenic rats 7 days after immuniza-
tion, when the immune response is mounted against autoantigen.
This up-regulation of Zfhep2 in early disease likely led to disrupted
Zfhep1 auto-regulation in later disease. Consequently, higher levels
of Zfhep1 and lower levels of IL2 were seen in the protected
DA.PVG-Eae23 rats 35 days after immunization. However,
repression of IL2 expression did not reflect ZEB1 levels, but
depended on Zfhep1 expression. This finding probably reflects that
the full-length variant contains both zinc-finger domains needed to
be fully functional [43]. We therefore postulate that the
mechanism by which Eae23b regulates EAE is through regulation
of alternative splicing of ZEB1 which in turn regulates IL2.
IL2 is involved in T cell development at multiple stages
[24,25,44–46]. The alpha-chain of the receptor for IL2 (IL2RA) is
a risk gene for MS and other autoimmune diseases [11,13,47,48].
IL2 was therefore our prime candidate mechanism for ZEB1
influence on neuroinflammation, supported by finding in the
congenic strain. We found decreased levels of Foxp3
+ cells, which
are likely to be Tregs [49,50], and higher levels of CD8
+
macrophages in the CNS of disease susceptible DA rats compared
to protected congenic rats. This difference was present in rats with
the same onset of disease and maximum clinical severity, likely
reflecting that DA.PVG-Eae23 rats recovered from the first bout of
disease to a larger extent than DA rats and had milder disease in
the chronic phase of EAE (Figure 3). The improved recovery rate
observed in congenic rats may reflect the enhanced Treg
population. In early disease, we observed a higher potential to
expand the Treg population in response to rMOG restimulation in
lymph node cells. Consistent with this, a higher number of Tregs
were present in the target organ later in disease. Previous studies
Table 2. DA.PVG-Eae23 is protected from EAE compared to DA.
Females Mean (SD) Males Mean (SD)
DA (N=12) D.P-Eae23 (N=13) DA (N=22) D.P-Eae23 (N=21)
Incidence 92% 69% 82% 76%
Day of Onset 14.8 (8.3) 22.5 (12.9) 19.6 (10.4) 21.9 (11.3)
Max EAE Score 2.8 (1.4) 1.5 (1.3)* 2.6 (1.6) 1.7 (1.2)*
Duration 19.7 (8.6) 10.1 (9.5)* 15.8 (8.9) 11.7 (10.2)
Cumulative EAE score 50.7 (32.7) 15.0 (17.0)** 38 (28) 23 (23.9)
Mann-Whitney U-test was used to compare clinical phenotypes between parental DA and DA.PVG-Eae23; p values #0.05 were considered significant, indicated by
*=p,0.05;
**=p,0.01. Abbreviations: SD = standard deviation.
doi:10.1371/journal.pone.0012716.t002
Table 3. Expected congenic phenotype values based on the (DA 6PVG.1AV1) G10 AIL.
Congenic Strain AIL Genotype Expected Phenotype Value
Eae23a Eae23b WL0
b INC
a ONS
b MAX
b DUR
b CUM
b
DA (62) DA DA 0.95 17% 35.88 0.36 1.67 3.59
D.P-Eae23 (98) PVG PVG 3.45** 47%*** 27.59*** 1.35*** 7.93*** 19.36***
Eae23-Het (30) DA/PVG DA/PVG 2.57 35%* 30.61 1.03 5.9 14.29
Rats that matched the genotype combinations captured in the congenic strains were selected from the AIL cohort. The number of AIL rats that were used to generate
the expected phenotype value for each congenic strain is indicated in parenthesis. Rats with DA genotype were compared to rats with either PVG or heterozygous
genotype in Eae23;
a= Fisher’s Exact Test,
b= Mann-Whitney U-test. p values #0.05 were considered significant, indicated by
*=p,0.05;
**=p,0.01;
***=p,0.001.
doi:10.1371/journal.pone.0012716.t003
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[51,52]. The higher infiltration rate of Foxp3
+ cells in protected
rats supports the protective role of Tregs and indicates that down-
regulated autoimmunity diminished the ‘‘inviting signal’’ to recruit
peripheral immune cells that cause disease exacerbation. Accord-
ingly, susceptible rats had higher recruitment of macrophages in
the CNS and developed more severe inflammation compared to
protected rats. This is possibly a consequence of dysregulation of
Tregs in DA rats. This speculation is consistent with involvement
of IL2. Mice that are deficient of IL2 and IL2RA (CD25) mount
strong immune responses that contribute to development of
autoimmune disease [53], and reduced IL2 levels correlate with
reduced CD4
+CD25
+ T cell function [54]. Additionally support-
ing the involvement of Tregs is that their frequency is normal in
MS patients compared to controls, but their suppressive function is
diminished [55]. Further study is required to understand the cell
populations in the CNS that contribute to disease development
and recovery. Therefore, detailed characterization of the kinetics
of CNS inflammation in our congenic strain over the course of
EAE need to be addressed in future studies. Alternative splicing is
Figure 4. CNS histopathology demonstrates less inflammation and demyelination in DA.PVG-Eae23 than DA. Spinal cord and brain
sections of DA.PVG-Eae23 congenic rats (the two left columns) and DA rats (the two right columns) with the same MAX score. Sections were stained
in the following order: spinal cord cross-sections (top row) and brain sections including optic nerve (row 2) were stained with Klu ¨ver (KL) and
Ha ¨malaun-Eosin (HE), respectively. Congenic rats revealed no signs of CNS inflammation and demyelination while DA rats showed severe loss of
myelin and cell infiltration at the sight of the lesion in the spinal cord white matter, as well as at the optic nerve. Staining of the spinal cord sections
against CD3 (row 3), CD8 (row 4) and Foxp3 (bottom row) revealed the higher recruitment of CD3
+ T cells and CD8
+ macrophages respectively to
inflammatory lesions in the DA rats and higher recruitment of Foxp3
+ T cells in DA.PVG-Eae23 congenic rats. Arrow heads point to cells with positive
staining and indicate the relative number of positive cells present.
doi:10.1371/journal.pone.0012716.g004
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mRNA, including exon extensions and deletions [56–58].
Bioinformatic analyses suggest that alternative splicing is a
significant component in generating diversity of function and
predict that the majority of human genes undergo alternative
splicing [57]. Splice variants may serve as homeostatic regulators
in healthy physiology and disease [59–61]. Isoform selection of
alternative splice forms may be involved in the pathogenesis of
many human diseases and animal models thereof, including
cancer and autoimmune diseases [62–65]. Cytotoxic T lympho-
cyte-associated antigen 4 (CTLA4, ENSG00000163599) has
demonstrated genetic linkage to a number of autoimmune
diseases, including MS [66–70], and involves genetic regulation
of alternative splice forms [71]. Other genes that regulate disease
by differential splice-variant expression are IL2RA and IL7R,
which may involve dysregulation of their membrane-bound and
soluble forms in MS patients [12,72,73]. For example, the C allele
of a risk SNP may contribute to skipping of alternatively spliced
exon 6 of IL7RA and alter the balance between splice forms [12].
Taken together, these findings indicate that expression and
signaling delivered by specific splice variants may play a critical
role in regulating autoimmune disease and illustrates the
importance of carefully dissecting gene expression data. Concord-
ingly, a SNP in ZEB1 has recently been suggested to associate with
rheumatoid arthritis, another autoimmune disease [74]. We
demonstrated that the balance between Zfhep1 and Zfhep2, the
splice variants of ZEB1, was altered in EAE-susceptible rats when
compared to protected rats. Considering the similarities between
MOG-EAE and MS, identifying underlying genes may either
reveal genes that regulate MS or identify pathogenic pathways of
importance for MS. ZEB1 is a strong candidate because of its
regulation of the IL2 pathway, which is important in MS and
EAE. Further functional studies of ZEB1 and the splice variants
may unravel novel pathways contributing to MS pathogenesis.
Materials and Methods
Animals
Ethics Statement. All experiments in this study were
approved and performed in accordance with the guidelines from
the Swedish National Board for Laboratory Animals and the
European Community Council Directive (86/609/EEC) under
the ethical permit N332/06 entitled ‘Genetic regulation,
pathogenesis and therapy of EAE, an animal model for multiple
sclerosis’, which was approved by the North Stockholm Animal
Ethics Committee (Stockholms Norra djurfo ¨rso ¨ksetiska na ¨mnd).
Rats were tested according to a health-monitoring program at the
National Veterinary Institute (Statens Veterina ¨rmedicinska
Anstalt, SVA) in Uppsala, Sweden. Inbred DA and PVG.1AV1
rats were originally obtained from the Zentralinstitut fu ¨r
Versuchstierzucht (Hannover, Germany) from which colonies
have been established at Karolinska Institutet (DA/Kini and
PVG.1AV1/Kini). All animals were bred and kept in 12 h light/
dark- and temperature-regulated rooms. Rats were housed in
polystyrene cages containing aspen wood shavings and had free
access to standard rodent chow and water.
Advanced Intercross Line. The AIL was established
between DA and MHC-identical PVG.1AV1 strains as
described previously [28]. Three G10 litters were produced of
Table 4. CNS Histopathology demonstrates protection from
EAE in DA.PVG-Eae23.
DA DA.PVG-Eae23
Mean (SD) Mean (SD)
Weight at immunization (grams) 162.9 (9.5) 153.5 (16.7)
Adjusted dose (mg MOG/g rat) 0.092 (0.005) 0.099 (0.011)
Incidence (%) 89 (33) 69 (48)
Day of Onset (day p.i.) 15.6 (9.4) 22.5 (12.9)
Max EAE Score 2.7 (1.2) 1.5 (1.3)*
Duration (days) 20 (8.5) 10.1 (9.5)*
Cumulative EAE score 46.8 (28.4) 15 (17)*
Spinal Cord Demyelination 1.8 (1.6) 0.09 (0.3)*
Spinal Cord Inflammation Index 0.58 (0.46) 0.14 (0.29)*
Brain Demyelination 2.6 (1.8) 0.35 (1.1)*
Demyelination in Optic Nerves 7/9 2/13*
Pons Involvement 1/9 0/13
Mann-Whitney U-test was used to compare histopathology phenotypes
between parental DA and DA.PVG-Eae23; p values #0.05 were considered
significant, indicated by *.
Abbreviations: SD = standard deviation, p.i. = post immunization.
doi:10.1371/journal.pone.0012716.t004
Figure 5. Regulatory T cell response to MOG recall in early disease. Day 7 p.i. lymph node cells from DA and DA.PVG-Eae23 were stained for
T reg markers and pre-gated for CD4
+ T cells using flow cytometry. A) Representative flow cytometry plot of CD4 (x-axis) and CD25 (y-axis) showing
the gate for the CD4
+CD25
+ population. B) Representative flow cytometry plot of Foxp3 (x-axis) and CD25 (y-axis) showing the gate for the
CD4
+CD25
+Foxp3
+ population. C) Fold change of CD4
+CD25
+Foxp3
+ sub-populations after MOG recall compared to ex vivo. Median values are
indicated by horizontal bars. Mann-Whitney U-test was used to compare the fold change; p values #0.05 were considered significant, ** =p#0.01.
Abbreviations: D.P-Eae23= DA.PVG-Eae23.
doi:10.1371/journal.pone.0012716.g005
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litters were similar in size and sex distribution.
Congenic strains. The congenic strains were established
from DA and PVG.1AV1 rats using a speed-congenic approach
with marker-assisted selection [75]. In brief, DA females were
mated with male offspring selected for PVG alleles within Eae23
and against PVG background contamination at 96 microsatellite
markers equally spaced throughout the genome (20 centiMorgan
intervals). DA females were used throughout the breeding
program to ensure that mitochondrial DNA was inherited from
Figure 6. Exon-level mRNA expression of ZEB1 in DA and PVG.1AV1 lymph nodes 7 days p.i. A) Exon-level expression of ZEB1
demonstrate that exon 4 had lower expression compared to all other exons. B) Schematic illustration of the splice variants Zfhep1 and Zfhep2 of rat
ZEB1 based on mRNA sequence. Exon 4 is specific for the Zfhep1 variant. White boxes represent untranslated exons, light grey boxes represent splice
variant-specific exons or sequences and dark grey boxes represent shared exons. C) Schematic illustration of the protein structure of Zfhep1 and
Zfhep2 based on amino acid sequence. Zinc finger 1 and part of zinc finger 2 are spliced out of Zfhep2.
doi:10.1371/journal.pone.0012716.g006
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intercrossed to produce homozygous DA.PVG-Eae23 congenic
rats, carrying PVG alleles between D17Rat8 at 27.6 Mb and
D17Rat37 at 75.8 Mb (Figure 3).
Induction and Clinical Evaluation of EAE
Recombinant rat MOG (amino acids 1–125 from the N
terminus) was expressed in Escherichia Coli and purified to
homogeneity by chelate chromatography [76]. Rats between 8
and 11 weeks of age were anesthetized with isoflurane (Abbott
Laboratories, Abbott Park, IL, USA) and immunized intrader-
mally in the dorsal tail base. Each animal received a 200 ml
inoculum containing MOG in phosphate buffered-saline (PBS)
(Life Technologies, Paisley, UK) emulsified 1:1 with incomplete
Freunds adjuvant (IFA) (Sigma-Aldrich, St. Louis, MO, USA).
Each MOG batch had slightly different potency, so titration
experiments were performed to determine comparable effective
doses. AIL rats were immunized with 20 mg of MOG per rat while
congenic rats were immunized with sex-specific MOG doses, 15
and 22 mg/rat in females (depending on MOG batch) and 30 mg/
rat in males. Animals were weighed and clinical signs of EAE were
evaluated daily from day 9–35 p.i. as previously described [28].
Phenotypes used for analysis were incidence of EAE (INC), onset
of clinical signs (ONS), duration of symptoms (DUR), maximum
and cumulative EAE scores (MAX and CUM, respectively).
Weight loss (WL) was calculated by subtracting the lowest weight
during the experiment from the weight at time of immunization
and expressing the difference as a percentage of the initial weight.
Genotype and Statistical Analysis
Genotyping. Genomic DNA was extracted from tail tips
according to a standard protocol [77]. Genotypes were determined
by polymerase chain reaction (PCR) amplification of microsatellite
markers as previously described [78]. For the AIL, forward
primers were end labelled with [c-
33P]ATP and the PCR products
were size fractionated on 6% polyacrylamide gels and visualized
by autoradiography. Primers were obtained from Proligo (Paris,
France). For the construction of the congenic strain, fluorophore-
conjugated primers were used (Applied Biosystems, Foster City,
CA, USA) and PCR products were size fractionated using an
electrophoresis capillary sequencer (ABI3730). Genotypes were
analyzed using the GeneMapper software (v. 3.7, Applied
Biosystems) [79] and all genotypes were manually evaluated by
2 independent observers.
Linkage Analysis of AIL. The genetic map was defined
using publicly available genome sequence (http://www.ensembl.
org/v.55). Determination of the QTL map position and the
confidence interval depends on the correct genomic positions of
microsatellite markers. The physical map was used for linkage
analysis which enabled comparison of linkage maps of sub-
populations. Linkage analysis was performed using R/qtl software
version 2.4.1 [80] to identify the QTLs of main effect and two-
dimensional scans were performed to identify epistatic
interactions. For calculation of linkage to phenotypes the binary
model was used for INC and Hailey-Knott regression was used for
DUR, MAX, CUM and WL, to generate maximum base 10
logarithm of the likelihood ratio (LOD) scores. Hailey-Knott
regression was chosen because it could include covariates, and we
tested that the model yielded similar results as a non-parametric or
two-part model.
To set the significance threshold, we computed the mean for
each family and the residual value from the family mean for each
rat and repeated the linkage analysis in the residual data set
(indicated in parenthesis in applicable tables) [28]. In addition, the
maximum LOD scores for the original one-dimensional scans
were all higher than 3.4, a suggested cut-off from simulated data
sets [30]. The conventional permutation method [81] could not be
Figure 7. Gene expression of candidate pathway genes in parental DA and PVG.1AV1. mRNA expression in lymph nodes collected day 7
p.i. from parental DA and PVG.1AV1 reveal differential gene expression of ZEB1 isoform Zfhep2. Median values are indicated by horizontal bars. Mann-
Whitney U-test was used to compare the mRNA expression; p values #0.05 were considered significant, ** =p#0.01. Abbreviations: RQ = relative
quantity. Gene names: ZEB1 = Zinc finger E-box-binding homeobox 1, IL2 = Interleukin 2, Zfhep1 = Zinc finger homeodomain enhancer-binding
protein 1 (NP_037296.1, splice variant 1) and Zfhep2 = Zinc finger homeodomain enhancer-binding protein 2 (ZEB1, splice variant 2).
doi:10.1371/journal.pone.0012716.g007
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family structure of the G10 compared with F2 generations for
which it was developed, while the traditional bootstrapping
method [82,83] could not be used to determine confidence
intervals because of the closely situated QTL. Confidence intervals
were defined using the closest marker outside a 1.5 LOD support
interval from the QTL peak location [84], approximately
equivalent to a 95% confidence interval [82].
Statistical Analysis. Kruskal–Wallis ranking test was used to
confirm the influence of peak markers defined in the linkage
analysis on phenotypes, and p values # 0.05 after Bonferroni
correction [85] were considered significant. The fit multiple QTL
model in R/qtl was used to statistically validate the independent
effect of each identified QTL. The probability for each QTL was
generated by simulating 1000 pedigrees sampled with replacement
from the observed individuals (N=428), and each was mapped
Figure 8. Differential ZEB1 isoform expression in DA.PVG-Eae23 and DA. Differential gene expression of ZEB1 is driven by a splice-variant
specific shift in balance. In lymph nodes collected day 7 p.i. from parental DA and DA.PVG-Eae23 (A – D), mRNA expression of Zfhep2 is up-regulated
in the congenic strain compared to parental DA. In spleen collected day 35 p.i. (E – H), Zfhep1 is up-regulated while Zfhep2, ZEB1 and IL2 are down-
regulated in DA.PVG-Eae23 compared to parental DA. Median values are indicated by horizontal bars. Mann-Whitney U-test was used to compare the
mRNA expression; p values #0.05 were considered significant, * =p#0.05 and ** =p#0.01. Abbreviations: D.P-Eae23= DA.PVG-Eae23, RQ = relative
quantity. A and E) ZEB1 = Zinc finger E-box-binding homeobox 1, B and F) IL2 = Interleukin 2, C and G) Zfhep1 = splice variant 1 of ZEB1
(NP_037296.1) D and H) Zfhep2 = splice variant 2 of ZEB1 (ZEB1).
doi:10.1371/journal.pone.0012716.g008
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Probability was calculated as the percentage of times the
maximum LOD (above threshold) was located within the
confidence interval of each QTL, as previously described [28].
To analyze the experiments with congenic strains, DA.PVG-Eae23
was compared with parental DA. To estimate the influence of
allele combinations of Eae23a and Eae23b on disease
characteristics, rats from the AIL cohort that carried the
genotypes captured in each congenic strain (DA.PVG-Eae23,
DA.PVG-Eae23-Heterozygous and DA) were selected. The
expected phenotype values for each congenic strain were based
on the average phenotype values within the corresponding AIL
group. AIL rats with DA genotype were compared to rats with
either PVG or heterozygous genotype in Eae23. ONS, MAX,
DUR and CUM were analyzed using the Mann–Whitney U-test
and Fisher’s exact test was used to compare INC. Calculations
were carried out using the PC versions of JMP v. 6.0.2 (SAS
Institute Inc., Cary, NC, USA). For in vitro experiments data were
analyzed using Mann-Whitney’s non-parametric ranking test
(GraphPad Prism 5.01, GraphPad, San Diego, USA). Median
was plotted. Statistical significance was determined as p-value
#0.05.
Immunohistochemistry
At day 35 p.i. thirteen DA.PVG-Eea23 rats and nine DA
controls were euthanized by asphyxiation using CO2 and perfused
with PBS followed by 4% paraformaldehyde. Immunohistochem-
ical analysis of dissected brains and spinal cords was performed on
paraformaldehyde fixed paraffin embedded sections. 0.4 mm thick
sections were stained with hematoxylin-eosin and luxol fast blue to
detect CNS inflammation and demyelination, respectively. The
inflammatory index was determined from the number and size of
inflammatory lesions on an average of twenty complete cross-
sections of the spinal cord and the brain of each animal, as
previously described [16].
Staining was performed with antibodies against the following
targets: mouse monoclonal a-CD8 (1:200, Serotec, UK), rabbit
monoclonal a-CD3 (1:150, Thermo Scientific, UK) and rat
monoclonal Foxp3 (1:1000, eBioscience, UK). Incubation with
specific primary antibodies was performed overnight at 4uC.
Incubation with biotinylated secondary antibody lasted for 1 hour
at RT followed by incubation with avidin-horseradish peroxidase
complex (HRP; Sigma Aldrich, Germany) for 1 hour at RT. The
visualisation of bound biotinylated secondary antibodies was
performed with 3,39 diaminobencidine (DAB)/H2O2-solution.
Expression analysis
Affymetrix. Four DA and four PVG.1AV1 rats were
euthanized using CO2 7 days post-EAE induction, before debut
of clinical disease signs. Draining inguinal lymph nodes were
collected and samples were prepared as previously described [33].
We used Affymetrix Exon 1.0 ST arrays to assess genome-wide
expression. Target labeling, as well as array hybridization, washing
and staining were performed as described in the GeneChip Whole
Transcript (WT) Sense Target Labeling manual (http://www.
affymetrix.com). Arrays were scanned using the GeneChip
Scanner 3000 7G (Affymetrix). Probe sequences for all
annotated genes within Eae23 are found in Table S2.
The microarray data is available in MIAME-compliant (mini-
mum information about a microarray experiment) format at the
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) [86]
under accession code E-MEXP-2237. CEL intensity files were
produced using GeneChip Operating Software version 1.4
(Affymetrix) and quality tested using the Affymetrix Expression
Console. Probe-level data were normalized using Robust Multi-
array Average (RMA) [87]. Detection of differential expression at
the exon and gene level was performed in Partek Genomics Suite
6.4 (Partek Inc., St.Louis, MO, USA). Data was summarized at the
gene level using a One-Step Tukey’s Biweight Algorithm, which
reduces the effect of outlier probe-sets (Statistical Algorithms
Description Document; Affymetrix-White-Paper). An ANOVA
model, using strain, condition and batch as co-factors, was used
to generate raw p values, while FDR was used for multiple
test corrections [88]. Genes with 5% FDR were classified as
differentially expressed.
RNA extraction and RT-PCR. For expression analysis in the
parental DA and PVG.1AV1 strains, six females of each strain
were immunized with MOG as described above at 12 weeks of
age. On day 7 p.i. animals were euthanized using CO2 and
inguinal lymph nodes were dissected out and snap-frozen in micro
tubes and stored at 270uC. For congenic strains, 5 DA and 5
DA.PVG-Eae23 female rats were sacrificed using CO2 at day 7 p.i.
and draining inguinal lymph nodes were collected. Lymph nodes
were placed in DMEM (Gibco-BRL, Grand Island, NY) enriched
with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-
streptomycin, 1% pyruvic acid (Life Technologies, Paisley,
Scotland) and 50 mM 2-Mercaptoethanol (complete media;
Gibco-BRL) before being mechanically separated by passing
through a mesh screen with the bolus of a syringe. Cells were spun
at 300 g and resuspended in complete media for counting. Cells
were allocated to ex vivo flow cytometry, cell culture or RT-PCR.
An additional 5 DA and 6 DA.PVG-Eae23 female rats were
sacrificed using CO2 at day 7 p.i. and draining inguinal lymph
nodes were collected and snap-frozen in micro tubes and stored at
270uC. Furthermore, 10 DA and 13 DA.PVG-Eae23 females
were immunized at 10–12 weeks of age and MOG-EAE was
evaluated for 35 days. On day 35 p.i. the rats were euthanized and
spleen was dissected out and snap-frozen in micro tubes and stored
at 270uC. Tissues were disrupted using Lysing Matrix D tubes
(MP Biomedicals, Irvine, CA, USA) on a FastPrep homogenizer
(MP Biomedicals).mRNA from cells and homogenates was
extracted using RNeasy mini columns (Qiagen Gmbh, Hilden,
Germany), including on column DNA-digestion. Reverse
transcription was performed using random hexamer primers
(Gibco) and Superscript Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). Real-time PCR was performed using an
ABI7900HT Fast Real-Time PCR System (Applied Biosystems
Inc., Foster City, CA, USA) with a two-step PCR protocol (50uC
for 2 min and 95uC for 10 min followed by 40 cycles of 95uC for
15 sec and 60uC for 60 sec), using SYBR green as reporter dye
(Applied Biosystems Inc.). Serial 2-fold dilutions from a pool of
ConA stimulated DA lymphocyte cDNA was used as standard for
assessment of relative efficiency of target amplification. We used
the DDCT method for relative quantification as the PCR
efficiencies between the target(s) and reference gene(s) were
relatively equivalent. Relative quantity (RQ) of expression was
calculated as 2
2DDCt (DDCt = (target gene - reference gene) –
average target gene). Primers sequences for the quantitative real
time PCR are found in Table S3.
In vitro experiment
Stimulation. For stimulation experiments 1610
6 cells/well
were plated in 48 well flat bottom plates (Nunc, Roskilde,
Denmark). Cells were stimulated with either: complete media,
0.5 mg/ml Concanavalin A (Sigma-Aldrich) or 25 mg/ml rMOG
for 24 hrs at 37uC and 5% CO2. Supernatants were collected for
IL-2 ELISA. Cells were spun down and used for flow cytometry.
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Assays. IL-2 ELISAs were performed according to
manufacturers’ recommendations (Biosource International,
California, USA) using 96-well flat-bottom ELISA plates (Nunc).
Supernatants from stimulation assays were collected at 24 hrs.
Flow Cytometry. Lymph node cells were washed with cold
PBS and resuspended in a further 100 ml of PBS. Cells were first
stained for extracellular CD4-PE-Cy5 and CD25-PE (20 min at
4uC; BD Biosciences, San Jose, USA) and thereafter fixed and
stained for intracellular Foxp3-APC according to manufacturers’
recommendations (eBioscience, San Diego, USA). Staining was
visualized on a FACSort (BD, Franklin Lakes, USA) with Cell
Quest (version 3.2.1f1, BD) and analyzed using FloJo (version 8.8).
Supporting Information
Figure S1 Summary of phenotype distribution in (DAxPV-
G.1AV1)G10 AIL rats. The y-axis shows the number of rats with
each phenotypic value. The clinical parameters are detailed in
Materials and Methods. A-B: Distribution of all 794 (DAxPV-
G.1AV1)G10 rats. C-G: Distribution of 224 (DAxPVG.1AV1)G10
rats that developed EAE. Abbreviations: M = males, F = females,
INC = incidence of EAE, WL = weight loss, CUM = cumulative
EAE score, MAX = maximum EAE score, DUR = duration of
EAE, ONS = day of onset of EAE, p.i. = post immunization.
Found at: doi:10.1371/journal.pone.0012716.s001 (0.14 MB
TIF)
Figure S2 Eae23 regulates EAE in AIL rats although males have
low power. Log-likelihood plots of Eae23 in 794 (DAxPV-
G.1AV1)G10 AIL rats. Linkage analysis performed in groups
stratified according to sex identified two separate QTLs strongly
linked to EAE phenotypes in females while males showed one
centered QTL below the threshold for significance. To investigate
the possibility of sex-specific QTLs or sex interacting with
genotype, we included sex as a covariate in the model. Sex was
not significantly contributing to the linkage of Eae23 to clinical
phenotypes. Males weighed more than females at the age of
immunization and the dose used was possibly suboptimal to
induce EAE in the male population, which reduced the power to
separate the QTLs in the joint analysis. Microsatellite marker
positions are indicated by vertical lines on the x-axis. A) Phenotype
codes: INC = light grey; ONS = dark grey; MAX = black;
DUR = black dashed; CUM = grey. B) Data stratified according
to sex compared with the complete cohort. MAX is a
representative for all clinical phenotypes. Group codes: All (N =
794) = black; Females (N = 428) = red; Males (N = 366) =
blue. C) Linkage analysis including sex as a covariate. Hailey-Knott
regressionmodel = black; Hailey-Knott regressionmodelincluding
sex as an additive covariate = blue dashed line; Hailey-Knott
regression model including sex as an interactive covariate = red
dotted line. MAX is a representative for all clinical phenotypes.
Marker location/information was retrieved from Ensembl Genome
Database (http://www.ensembl.org v.55).
Found at: doi:10.1371/journal.pone.0012716.s002 (0.15 MB
PDF)
Figure S3 IL-2 protein expression in DA.PVG-Eae23 and
parental DA. IL-2 protein expression in lymph nodes collected
day 7 p.i., measured by Antibody Enzyme Linked ImmunoSor-
bent Assays (ELISA), reveals no differences between DA.PVG-
Eae23 and parental DA. Median values are indicated by
horizontal bars. Mann-Whitney U-test was used to compare IL-
2 levels; p values #0.05 were considered significant. Abbrevia-
tions: D.P-Eae23 = DA.PVG-Eae23, ConA = Concanavalin A,
rMOG = recombinant myelin oligodendrocyte glycoprotein. A)
IL-2 protein concentration in picograms per milliliter in
supernatant from ConA stimulated lymph node cells. B) IL-2
protein concentration in picograms per milliliter in supernatant
from rMOG stimulated lymph node cells.
Found at: doi:10.1371/journal.pone.0012716.s003 (0.70 MB TIF)
Table S1 Primer sequences were retrieved from Ensembl
Genome Database (http://www.ensembl.org v.55). a Positions
are given in megabasepair. The skewing of genotype distributions
reflect regions of genome that are becoming fixed in the
population due to the genetic drift within the breeding couples
used (50 per generation). The region between markers D17Got49
and D17Mgh5 has an overrepresentation of DA/DA genotype
(,29% in the 7th AIL generation and ,35% in the 10th AIL
generation) and marker D17Rat95 has drifted toward PVG/PVG
genotype. The minimum number of individuals with a particular
genotype was 68 rats, which should be sufficient for linkage.
Additionally, genotyping of selected markers within these regions
were repeated to ensure that genotypes were correctly scored.
Found at: doi:10.1371/journal.pone.0012716.s004 (0.04 MB
DOC)
Table S2 mRNA expression in lymph nodes collected day 7 p.i.
from parental DA and PVG.1AV1 measured by Affymetrix Exon
1.0 ST arrays. Data was summarized at the gene level using a
One-Step Tukey’s Biweight Algorithm and an ANOVA model
was used to generate raw p values. Fold change was calculated as
DA expression/PVG.1AV1 expression.
Found at: doi:10.1371/journal.pone.0012716.s005 (0.04 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0012716.s006 (0.03 MB
DOC)
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